Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies

References

• Rix U, Hantschel O, Duernberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib, reveal novel kinase and nonkinase targets. Blood. 2007 Dec 1;110(12):4055–4063.
   PubMed Web of Science ®Google Scholar
• Manley PW, Cowan-Jacob SW, Mestan J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim Biophys Acta. 2005 Dec 30;1754(1–2):3–13.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Akin C, Manshouri T, et al. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leuk Res. 2006 Nov;30(11):1365–1370.
   PubMed Web of Science ®Google Scholar
• Cortes J, O’Brien S, Jabbour E, et al. Efficacy of nilotinib (AMN107) in patients (Pts)with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP). Blood. 2007 Nov 16;110(11):29.
   Web of Science ®Google Scholar
• Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005 Feb;7(2):129–141.
   PubMed Web of Science ®Google Scholar
• Golemovic M, Verstovsek S, Giles F, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res. 2005 Jul 1;11(13):4941–4947.
   PubMed Web of Science ®Google Scholar
• O’Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005 Jun 1;65(11):4500–4505.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020 Jun;95(6):691–709.
   PubMed Web of Science ®Google Scholar
• Sacha T, Saglio G. Nilotinib in the treatment of chronic myeloid leukemia. Future Oncol. 2019 Mar;15(9):953–966.
   PubMed Web of Science ®Google Scholar
• Shin J, Koh Y, Yoon SH, et al. A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: eNESTKorea. Cancer Med. 2018 May;7(5):1814–1823.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Apr;34(4):966–984.
   PubMed Web of Science ®Google Scholar
• Fachi MM, Tonin FS, Leonart LP, et al. Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: a network meta-analysis. Br J Clin Pharmacol. 2019 Oct;85(10):2280–2291.
   PubMed Web of Science ®Google Scholar
• Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016 Aug;30(8):1648–1671.
   PubMed Web of Science ®Google Scholar
• Moslehi JJ, Deininger M. Tyrosine kinase inhibitor–associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;33(35):4210–4218.
   PubMed Web of Science ®Google Scholar
• Tajiri K, Aonuma K, Sekine I. Cardiovascular toxic effects of targeted cancer therapy. Jpn J Clin Oncol. 2017 Sep 1;47(9):779–785.
   PubMed Web of Science ®Google Scholar
• Jain P, Kantarjian H, Boddu PC, et al. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv. 2019 Mar 26;3(6):851–861.
   PubMed Web of Science ®Google Scholar
• Breccia M, Molica M, Alimena G. How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated review. Leuk Res. 2014 Dec;38(12):1392–1398.
   PubMed Web of Science ®Google Scholar
• Malek R, Davis SN. Tyrosine kinase inhibitors under investigation for the treatment of type II diabetes. Expert Opin Investig Drugs. 2016;25(3):287–296.
   PubMed Web of Science ®Google Scholar
• Constance C, Trudeau L, Jolicoeur EM, et al. Cardiologist’s perspective to the European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;31(3):771–772.
   PubMed Web of Science ®Google Scholar
• Wang JX, Shen ZX, Saglio G, et al. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: eNESTchina. Blood. 2015 Apr 30;125(18):2771–2778.
   PubMed Web of Science ®Google Scholar
• Rosti G, Palandri F, Castagnetti F, et al. Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. Blood. 2009 Dec 3;114(24):4933–4938.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Jones D, O’Brien S, et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol. 2010 Jan 20;28(3):392–397.
   PubMed Web of Science ®Google Scholar
• Saydam G, Haznedaroglu IC, Kaynar L, et al. Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: updated results with 2 years of follow-up. Hematology. 2018 Dec;23(10):771–777.
   PubMed Web of Science ®Google Scholar
• Nakamae H, Fukuda T, Nakaseko C, et al. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial. Int J Hematol. 2018 Mar;107(3):327–336.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016 May;30(5):1044–1054.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Rosti G, Cross NC, et al. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia. 2016 Jan;30(1):57–64.
   PubMed Web of Science ®Google Scholar
• Masarova L, Cortes JE, Patel KP, et al. Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. Cancer-Am Cancer Soc. 2020 Apr 1;126(7):1448–1459.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Hughes TP, Larson RA, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: eNESTnd 10-year analysis. Leukemia. 2021 Feb;35(2):440–453.
   PubMed Web of Science ®Google Scholar
• Giles FJ, Le Coutre PD, Pinilla-Ibarz J, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013 Jan;27(1):107–112.
   PubMed Web of Science ®Google Scholar
• Nicolini FE, Turkina A, Shen ZX, et al. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. Cancer-Am Cancer Soc. 2012 Jan 1;118(1):118–126.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011 Jan 27;117(4):1141–1145.
   PubMed Web of Science ®Google Scholar
• Deininger MW, Manley P. What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML? Leuk Res. 2012 Mar;36(3):253–261.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Han X, Kantarjian H, et al. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood. 2009 Jul 9;114(2):261–263.
   PubMed Web of Science ®Google Scholar
• Fachi MM, Tonin FS, Leonart LP, et al. Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: a systematic review and network meta-analysis. Eur J Cancer. 2018 Nov;104:9–20.
   PubMed Web of Science ®Google Scholar
• Ratajczak MZ, Luger SM, Deriel K, et al. Role of the kit protooncogene in normal and malignant human hematopoiesis. Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1710–1714.
   PubMed Web of Science ®Google Scholar
• Ashman LK. The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell B. 1999 Oct;31(10):1037–1051.
   PubMed Web of Science ®Google Scholar
• Belloc F, Airiau K, Jeanneteau M, et al. The stem cell factor-c-KIT pathway must be inhibited to enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cells. Leukemia 2009 Apr;23(4):679–685.
   PubMed Web of Science ®Google Scholar
• Corbin AS, O’Hare T, Gu Z, et al. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors. Cancer Res. 2013 Sep 15;73(18):5775–5786.
   PubMed Web of Science ®Google Scholar
• Deininger MW, Shah NP, Altman JK, et al. Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020 Oct 1;18(10):1385–1415.
   PubMed Web of Science ®Google Scholar
• Hartmann JT, Haap M, Kopp HG, et al. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab. 2009 Jun;10(5):470–481.
   PubMed Web of Science ®Google Scholar
• Basso FG, Boer CC, Correa ME, et al. Skin and oral lesions associated to imatinib mesylate therapy. Support Care Cancer. 2009 Apr;17(4):465–468.
   PubMed Web of Science ®Google Scholar
• Valeyrie L, Bastuji-Garin S, Revuz J, et al. Adverse cutaneous reactions to imatinib (ST1571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol. 2003 Feb;48(2):201–206.
   PubMed Web of Science ®Google Scholar
• Brouard M, Saurat J. Cutaneous reactions to STI571. New Engl J Med. 2001 Aug 23;345(8):618–619.
   PubMed Web of Science ®Google Scholar
• Scheinfeld N. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol. 2006 Mar;5(3):228–231.
   PubMedGoogle Scholar
• Verstovsek S, Giles FJ, Quintas-Cardama A, et al. Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells. Leuk Res. 2006 Dec;30(12):1499–1505.
   PubMed Web of Science ®Google Scholar
• Stover EH, Chen J, Lee BH, et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood. 2005 Nov 1;106(9):3206–3213.
   PubMed Web of Science ®Google Scholar
• Abbaspour Babaei M, Kamalidehghan B, Saleem M, et al. Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells. Drug Des Devel Ther. 2016;10:2443–2459.
   PubMed Web of Science ®Google Scholar
• Tanaka C, Yin OQ, Sethuraman V, et al. Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther. 2010 Feb;87(2):197–203.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Cortes J. Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases. Future Oncol. 2008 Oct;4(5):611–621.
   PubMed Web of Science ®Google Scholar
• Giles FJ, O’Dwyer M, Swords R. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia. 2009 Oct;23(10):1698–1707.
   PubMed Web of Science ®Google Scholar
• Kazlauskas A. PDGFs and their receptors. Gene. 2017 May;30(614):1–7.
   Google Scholar
• Östman A, Heldin CH. PDGF receptors as targets in tumor treatment. Advances in Cancer Research. 2007;97:247–274.
   PubMed Web of Science ®Google Scholar
• Raica M, Cimpean AM. Platelet-derived growth factor (PDGF)/PDGF Receptors (PDGFR) axis as target for antitumor and antiangiogenic therapy. Pharmaceuticals. 2010 Mar 11;3(3):572–599.
   Google Scholar
• Huguet F, Cayuela JM, Cambier N, et al. Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukaemia in chronic phase: a prospective observational study in daily clinical practice. Br J Haematol. 2019 Dec;187(5):615–626.
   PubMed Web of Science ®Google Scholar
• Caocci G, Mulas O, Annunziata M, et al. Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors. Int J Cardiol. 2020 Feb 15;301:163–166.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):337–340.
   PubMed Web of Science ®Google Scholar
• Campia U, Gerhard-Herman M, Piazza G, et al. Peripheral artery disease: past, present, and future. Am J Med. 2019 Oct;132(10):1133–1141.
   PubMed Web of Science ®Google Scholar
• Schurch KA, Sixt S, Jeanneret C, et al. Update on the current diagnosis and therapy of peripheral arterial occlusive disease. Ther Umsch. 2018 Aug;75(8):478–488.
   PubMed Web of Science ®Google Scholar
• Poredos P, Poredos P. Peripheral arterial occlusive disease and perioperative risk. Int Angiol. 2018 Apr;37(2):93–99.
   PubMed Web of Science ®Google Scholar
• Caocci G, Mulas O, Bonifacio M, et al. Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. Int J Cardiol. 2019;288:124–127.
   PubMed Web of Science ®Google Scholar
• Mulas O, Caocci G, Stagno F, et al. Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors. Ann Hematol. 2020 Jul;99(7):1525–1530.
   PubMed Web of Science ®Google Scholar
• Atallah E. Nilotinib cardiac toxicity: should we still be concerned? Leuk Res. 2011 May;35(5):577–578.
   PubMed Web of Science ®Google Scholar
• Yang B, Papoian T. Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome. J Appl Toxicol. 2012 Dec;32(12):945–951.
   PubMed Web of Science ®Google Scholar
• Caocci G, Mulas O, Capodanno I, et al. Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. Ann Hematol. 2021 Jan;3.
   Google Scholar
• Manouchehri A, Kanu E, Mauro MJ, et al. Tyrosine kinase inhibitors in leukemia and cardiovascular events: from mechanism to patient care. Arterioscler Thromb Vasc Biol. 2020 Feb;40(2):301–308.
   PubMed Web of Science ®Google Scholar
• Doherty KR, Wappel RL, Talbert DR, et al. Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245–255.
   PubMed Web of Science ®Google Scholar
• Gover-Proaktor A, Granot G, Pasmanik-Chor M, et al. Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells. Leuk Lymphoma. 2019 Jan;60(1):189–199.
   PubMed Web of Science ®Google Scholar
• Wang XK, Feuerstein GZ, Gu JL, et al. Interleukin-1-beta induces expression of adhesion molecules in human vascular smooth-muscle cells and enhances adhesion of leukocytes to smooth-muscle cells. Atherosclerosis. 1995 May;115(1):89–98.
   PubMed Web of Science ®Google Scholar
• Sukegawa M, Wang X, Nishioka C, et al. The BCR/ABL tyrosine kinase inhibitor, nilotinib, stimulates expression of IL-1beta in vascular endothelium in association with downregulation of miR-3p. Leuk Res. 2017 Jul;58:83–90.
   PubMed Web of Science ®Google Scholar
• Franscini N, Bachli EB, Blau N, et al. Gene expression profiling of inflamed human endothelial cells and influence of activated protein C. Circulation. 2004 Nov 2;110(18):2903–2909.
   PubMed Web of Science ®Google Scholar
• Seynhaeve AL, Rens JA, Schipper D, et al. Exposing endothelial cells to tumor necrosis factor-alpha and peripheral blood mononuclear cells damage endothelial integrity via interleukin-1ss by degradation of vascular endothelial-cadherin. Surgery. 2014 Mar;155(3):545–553.
   PubMed Web of Science ®Google Scholar
• Ikezoe T. Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment using recombinant human soluble thrombomodulin. Int J Hematol. 2014 Jul;100(1):27–37.
   PubMed Web of Science ®Google Scholar
• Ikezoe T. Thrombomodulin/activated protein C system in septic disseminated intravascular coagulation. J Intensive Care. 2015;3(1):1.
   PubMedGoogle Scholar
• Hadzijusufovic E, Albrecht-Schgoer K, Huber K, et al. Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site. Leukemia. 2017 Nov;31(11):2388–2397.
   PubMed Web of Science ®Google Scholar
• Cirmi S, El Abd A, Letinier L, et al. Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA Adverse Event Reporting System Database (FAERS). Cancers (Basel). 2020 Mar 30;12(4):826.
   PubMed Web of Science ®Google Scholar
• Hock JM, Canalis E. Platelet-derived growth-factor enhances bone cell replication, but not differentiated function of osteoblasts. Endocrinology. 1994 Mar;134(3):1423–1428.
   PubMed Web of Science ®Google Scholar
• Fiedler J, Etzel N, Brenner RE. To go or not to go: migration of human mesenchymal progenitor cells stimulated by isoforms of PDGF. J Cell Biochem. 2004 Nov 15;93(5):990–998.
   PubMed Web of Science ®Google Scholar
• Mitlak BH, Finkelman RD, Hill EL, et al. The effect of systemically administered PDGF-BB on the rodent skeleton. J Bone Miner Res. 1996 Feb;11(2):238–247.
   PubMed Web of Science ®Google Scholar
• Chaudhary LR, Hruska KA. The cell survival signal Akt is differentially activated by PDGF-BB, EGF, and FGF-2 in osteoblastic cells. J Cell Biochem. 2001;81(2):304–311.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011 Sep;12(9):841–851.
   PubMed Web of Science ®Google Scholar
• Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: eNESTnd 3-year follow-up. Leukemia. 2012 Oct;26(10):2197–2203.
   PubMed Web of Science ®Google Scholar
• Saglio G, Hochhaus A, Hughes TP, et al. ENESTnd Update: nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) with newly diagnosed chronic myeloid leukemia in Chronic Phase (CML-CP) and the impact of Early Molecular Response (EMR) and sokal risk at diagnosis on long-term outcomes. Blood. 2013 Nov 15;122(21): 92-92.
   PubMed Web of Science ®Google Scholar
• Abumiya M, Takahashi N, Niioka T, et al. Influence of UGT1A1 6, 27, and 28 polymorphisms on nilotinib-induced hyperbilirubinemia in Japanese patients with chronic myeloid leukemia. Drug Metab Pharmacokinet. 2014;29(6):449–454.
   PubMed Web of Science ®Google Scholar
• Ai L, Zhu L, Yang L, et al. Selectivity for inhibition of nilotinib on the catalytic activity of human UDP-glucuronosyltransferases. Xenobiotica. 2014 Apr;44(4):320–325.
   PubMed Web of Science ®Google Scholar
• Qosa H, Avaritt BR, Hartman NR, et al. In vitro UGT1A1 inhibition by tyrosine kinase inhibitors and association with drug-induced hyperbilirubinemia. Cancer Chemother Pharmacol. 2018 Nov;82(5):795–802.
   PubMed Web of Science ®Google Scholar
• Singer JB, Shou Y, Giles F, et al. UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia. 2007 Nov;21(11):2311–2315.
   PubMed Web of Science ®Google Scholar
• Breccia M, Muscaritoli M, Gentilini F, et al. Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. Leuk Res. 2007 Dec;31(12):1770–1772.
   PubMed Web of Science ®Google Scholar
• Saglio G, Larson RA, Hughes TP, et al. Efficacy and safety of nilotinib in Chronic Phase (CP) Chrome Myeloid Leukemia (CML) Patients (Pts) with type 2 diabetes in the ENESTnd trial. Blood. 2010 Nov 19;116(21):1405–1406.
   PubMedGoogle Scholar
• Delphine R, Gautier JF, Breccia M, et al. Incidence of hyperglycemia by 3 years in Patients (Pts) with newly diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) treated with Nilotinib (NIL) or Imatinib (IM) in ENESTnd. Blood. 2012 Nov 16;120(21): 1686-1686.
   Web of Science ®Google Scholar
• Iurlo A, Orsi E, Cattaneo D, et al. Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem? Oncotarget. 2015 Oct 20;6(32):33944–33951.
   PubMed Web of Science ®Google Scholar
• Romero-Ventosa EY, Otero-Millan L, Gonzalez-Costas S, et al. Effect of tyrosine kinase inhibitors on the glucose levels in diabetic and nondiabetic patients. Indian J Cancer. 2017 Jan-Mar;54(1):136–143.
   PubMed Web of Science ®Google Scholar
• Racil Z, Razga F, Drapalova J, et al. Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia. Haematologica. 2013 Oct;98(10):e124-e126.
   PubMed Web of Science ®Google Scholar
• Racil Z, Koritakova E, Sacha T, et al. Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy. Am J Hematol. 2018 Oct;93(10):E342–E345.
   PubMed Web of Science ®Google Scholar
• Hagerkvist R, Jansson L, Welsh N. Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet. Clin Sci (Lond). 2008 Jan;114(1):65–71.
   PubMed Web of Science ®Google Scholar
• Xia CQ, Zhang P, Li S, et al. C-Abl inhibitor imatinib enhances insulin production by beta cells: c-Abl negatively regulates insulin production via interfering with the expression of NKx2.2 and GLUT-2. Plos One. 2014;9(5):e97694.
   PubMed Web of Science ®Google Scholar
• Ito Y, Miyamoto T, Chong Y, et al. Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin. Int J Hematol. 2013 Jan;97(1):135–138.
   PubMed Web of Science ®Google Scholar
• Alhawiti N, Burbury KL, Kwa FA, et al. The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state. Thromb Res. 2016 Sep;145:54–64.
   PubMed Web of Science ®Google Scholar
• The FDA Database. [cited 2021 Feb 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022068s033lbl.pdf
   Google Scholar